Answers are grounded in this paper and cite their sources.
Data on estimation of genetic polymorphism thiopurine methyltransferase (ТРМТ) at 97 children of different ages with acute lymphoblastic leukemia (ALL) presented. Studied frequency characteristics of TPMT genotypes: *1 – 90.7 %, *3A – 8.3 %, *3C – 1.0 % comparable with published data. During the analysis of connection of genetic polymorphism TPMT c toxicity of treatment on ALL-MB-2002 protocol it was established significant predominance of severe hematological toxicity at heterozygous patients with mutant alleles in comparison with “wild type” patients. Increasing of severe neutropenia on consolidation stages showed in case of genetic polymorphism of TPMT. Genetic polymorphism did not affect results of ALL treatment. Correlation between TPMT polymorphism and second cancer established.
No takes yet. Share an insight, caveat, or question.
Petina et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: